This could perhaps be used in combination with oliogodendrocyte‐associated autoantigens to control MS or other autoantigens, such as thyroid antigens to treat the alemtuzumab‐induced autoimmune diseases that are highly prevalent in MS.11, 12, 13, 14 This hypothesis was investigated using a mouse CD52‐specific mAb in relapsing EAE. This evidence concerns the gene CD52 and myeloid sarcoma.